SV-AI-001

SV-AI-001 is an investigational preclinical-stage in vivo chimeric antigen receptor (CAR) therapy being developed by SunVax mRNA Therapeutics for the treatment of systemic lupus erythematosus (SLE). The therapeutic candidate utilizes SunVax's proprietary Cell Type Specific Delivery (CTSD) platform, which is an advanced lipid nanoparticle (LNP)-based delivery system engineered to target mRNA specifically to immune cells, such as T cells. By delivering mRNA encoding a CAR directly to the target cell population in vivo, SV-AI-001 aims to generate transient CAR-expressing cells to deplete pathogenic immune cells involved in SLE, while avoiding the complex ex vivo manufacturing processes associated with traditional CAR-T cell therapies. The specific CAR target has not been publicly disclosed.